César Serrano
YOU?
Author Swipe
View article: MITF regulates autophagy and extracellular vesicle cargo in gastrointestinal stromal tumors
MITF regulates autophagy and extracellular vesicle cargo in gastrointestinal stromal tumors Open
The role of Microphthalmia-associated Transcription Factor (MITF) in gastrointestinal stromal tumors (GISTs) remains unclear, although previous studies suggest it contributes to tumor growth regulation. Previously, we demonstrated that MIT…
View article: SEOM-AEEMT consensus on occupational cancer and cancer-associated disability
SEOM-AEEMT consensus on occupational cancer and cancer-associated disability Open
Cancer is one of the main causes of morbidity and mortality in Spain and has a significant impact in the workplace, where exposure to carcinogens in the work environment can increase the risk of developing this disease. The lack of communi…
View article: Breaking the redundancy: TAZ outperforms YAP1 in GIST progression
Breaking the redundancy: TAZ outperforms YAP1 in GIST progression Open
Background Gastrointestinal stromal tumors (GIST) are mainly caused by gain-of-function mutations in KIT or PDGFRA genes and are the most common neoplasms of the digestive tract. Imatinib (IM), a tyrosine kinase inhibitor (TKI) targeting t…
View article: DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas
DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas Open
Background: DNA damage response (DDR) pathway alterations contribute to genomic instability and malignant progression in several cancers. Methods: We retrospectively reviewed molecular profiles from 5309 sarcoma patient samples, including …
View article: Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation
Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation Open
Introduction Gastrointestinal stromal tumors (GISTs) are the most common sarcoma subtype. Patients with unresectable or metastatic GISTs harboring the D842V mutation in the PDGFRA gene have a poor prognosis due to intrinsic resistance to i…
View article: Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth
Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth Open
Gastrointestinal stromal tumors (GISTs) comprise about 80% of mesenchymal neoplasms in the gastrointestinal tract. Although imatinib mesylate is the preferred treatment, the development of drug resistance highlights the need for novel ther…
View article: SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024)
SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024) Open
Soft-tissue sarcomas are rare, diverse malignant tumors of mesenchymal origin, requiring diagnosis and treatment by a specialized multidisciplinary team. Initial assessment includes radiology and biopsy, followed by wide surgical resection…
View article: The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations Open
Somatic KIT activating mutations drive most gastrointestinal stromal tumors (GISTs). Disease progression eventually develops with first-line imatinib, commonly due to KIT secondary mutations, and different kinase inhibitors have various le…
View article: Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations Open
Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the histor…
View article: KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape Open
PURPOSE Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary KIT mutations, and clonal heterogeneity of these secondary mutations represents a major treatment obstacle. KIT inhibitors used after imatinib have c…
View article: Supplementary Table S2 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Supplementary Table S2 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Supplementary Table S2. Representativeness of the study participants with KIT-mutant gastrointestinal stromal tumors.
View article: Data from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Data from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Purpose:The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–PDGFRA-mutant gastrointestinal stromal tumors (GISTs) from the phase I NAVIGATOR and phase I/II CS3007–001 trials.…
View article: Supplementary Figure S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Supplementary Figure S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment with avapritinib 300 mg QD.
View article: Supplementary Table S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Supplementary Table S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Supplementary Table S1. Baseline demographics and disease characteristics of patients with GIST harboring only KIT mutations treated with avapritinib 300 mg QD in the phase I NAVIGATOR study (n = 131) and phase I/II CS3007-101 China bridgi…
View article: Supplementary Figure S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Supplementary Figure S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment with avapritinib 300 mg QD.
View article: Data from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Data from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Purpose:The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–PDGFRA-mutant gastrointestinal stromal tumors (GISTs) from the phase I NAVIGATOR and phase I/II CS3007–001 trials.…
View article: Supplementary Table S2 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Supplementary Table S2 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Supplementary Table S2. Representativeness of the study participants with KIT-mutant gastrointestinal stromal tumors.
View article: Supplementary Table S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Supplementary Table S1 from Clinical Benefit of Avapritinib in <i>KIT-</i>Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Open
Supplementary Table S1. Baseline demographics and disease characteristics of patients with GIST harboring only KIT mutations treated with avapritinib 300 mg QD in the phase I NAVIGATOR study (n = 131) and phase I/II CS3007-101 China bridgi…
View article: Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial Open
INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal stromal tumor who had disease progression on or intolerance to imatinib and who were randomized to once-daily ripretinib 150 mg or sunitinib 50 mg. …
View article: Novel trial designs for patients with gastrointestinal stromal tumor
Novel trial designs for patients with gastrointestinal stromal tumor Open
The unique difficulties associated with clinical trial development in rare neoplasms can sometimes make them impractical due to their rarity and heterogeneity. In selected populations, researchers may resort to placebo-controlled randomize…
View article: Recent advances in gastrointestinal stromal tumors: where are we going?
Recent advances in gastrointestinal stromal tumors: where are we going? Open
Gastrointestinal Stromal Sarcomas (GIST) are mesenchymal neoplasms whose incidence accounts for 1-2% of digestive tumors, being located in the stomach (55-60%) and small intestine (30%).The most important advances in recent years are focus…
View article: Tracking genome evolution in single cell clones reveals the rates and features of copy number alterations generated by ongoing chromosomal instability in cancer
Tracking genome evolution in single cell clones reveals the rates and features of copy number alterations generated by ongoing chromosomal instability in cancer Open
Cancer genomes exhibit extensive chromosomal alterations caused by ongoing Chromosomal Instability (CIN). The ensuing cell-cell heterogeneity facilitates evolution and cancer cell plasticity that can drive therapy resistance, yet cancer CI…
View article: Data from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Data from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study Open
Purpose:Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed …
View article: Table S1 from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Table S1 from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study Open
Supplementary Table S1 shows the outcomes of KIT/PDGFRA WT patients
View article: Table S1 from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Table S1 from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study Open
Supplementary Table S1 shows the outcomes of KIT/PDGFRA WT patients
View article: Data from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Data from Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study Open
Purpose:Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed …
View article: Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective
Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective Open
PURPOSE Mutations of the KIT gene are the molecular hallmark of most GI stromal tumors (GISTs). Imatinib has revolutionized GIST treatment. Adjuvant imatinib for 3 years is the standard of care for high-risk resected GIST. However, the GIS…